Últimas noticias sobre HOOKIPA Pharma (NASDAQ:HOOK) Bolsa

HOOKIPA Pharma

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.

HOOKIPA Pharma Inc

Hooker Furnishings Corporation - Common Stock

Hooker Furnishings Corp

Loop Capital analyst Rob Sanderson maintains Maplebear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) with a Buy and lowers the price target from $56 to $52.

News

Price Target

Analyst Ratings

CART

Loop Capital Maintains Buy on Maplebear, Lowers Price Target to $52

Global

MSFT

Microsoft Says To Invest Additional 5.4 Billion Rand In South Africa AI Infrastructure

RBC Capital analyst Rishi Jaluria maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Outperform and lowers the price target from $400 to $320.

RBC Capital Maintains Outperform on MongoDB, Lowers Price Target to $320

WIIM

Eaton Corporation shares are trading lower after RBC Capital lowered its price target on the stock from $405 to $376.

Cracker Barrel Old Country Store, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44163329/cracker-barrel-reports-second-quarter-fiscal-2025-results-and-increases-guidance" rel="noreferrer noopener">trading higher on Thursday.</a>
The company reported second-quarter adjusted earnings per share of $1.38 beating the street view of $1.00. Quarterly sales of $949.44 million (+1.5% year over year), outpaced the analyst consensus estimate of $943.58 million.
Comparable store restaurant sales increased 4.7%, and comparable store retail sales increased 0.2%.
Adjusted EBITDA was $74.6 million, a 19.6% increase compared to the prior year&#8217;s adjusted EBITDA of $62.4 million. Adjusted EBITDA margin expanded to 7.9% from 6.7% in the year-ago period.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/03/44164241/trump-administration-weighs-sea-inspections-of-iranian-oil-tankers" rel="noreferrer noopener">Trump Administration Weighs Sea Inspections Of Iranian Oil Tankers</a>
&#8220;Despite some recent industry-wide softness, these results, together with the continued improvements in key guest and operational metrics and the initiatives we have planned for our important fourth quarter, make us confident in raising our financial outlook for the remainder of the year,&#8221; Cracker Barrel President and Chief Executive Officer&nbsp;Julie Masino&nbsp;said.
The company&#8217;s quarterly dividend of&nbsp;$0.25&nbsp;per share is payable on&nbsp;May 14, 2025,&nbsp;to shareholders of record as of&nbsp;April 11, 2025.
Outlook: Cracker Barrel revises FY25 total revenue outlook from $3.4 billion &#8211; $3.5 billion to $3.45 billion &#8211; $3.50 billion (estimate: $3.46 billion).
Adjusted EBITDA is expected in the range of&nbsp;$210 million&nbsp;to&nbsp;$220 million&nbsp;versus the previous outlook of&nbsp;$200 million&nbsp;to&nbsp;$215 million.
Price Action: CBRL shares are trading higher by 20.6% to $48.59 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44163875/burlington-beats-earnings-sales-in-q4-stock-jumps" target="_blank" rel="noreferrer noopener">Burlington Stock Jumps As Q4 Earnings Crush Estimates, But CEO Warns Of &#8216;Uncertain&#8217; 2025 Outlook</a></li>
</ul>

Earnings

Equities

Guidance

Markets

Movers

General

CBRL

Cracker Barrel Stock Jumps On Q2 Earnings Beat, Raises FY25 Outlook

Trading Ideas

ACON

Aclarion Shares Halted On Circuit Breaker To The Downside, Stock Now Down -81%

On Wednesday,&nbsp;the FDA approved&nbsp;ARS Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) neffy&nbsp;1 mg&nbsp;(epinephrine nasal spray) for Type I Allergic Reactions, including anaphylaxis, in children who are aged 4 years and older and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">weigh 15 to &lt; 30 kilograms</a>.
The approval represents the first significant innovation in the delivery of epinephrine for this patient population<a href="https://www.benzinga.com/pressreleases/25/03/g44151949/ars-pharmaceuticals-announces-fda-approval-of-neffy-1-mg-epinephrine-nasal-spray-for-type-i-allerg" target="_blank" rel="noreferrer noopener"> in more than 35 years</a>. 
Approval of neffy 1 mg follows FDA approval for neffy 2 mg for children and adults weighing 30kg and for EURneffy in the EU by the European <a href="https://www.benzinga.com/general/biotech/24/08/40531242/newly-approved-ars-pharmaceuticals-needle-free-neffy-offers-convenience-over-epipen-for-allergic-" target="_blank" rel="noreferrer noopener">Commission in August 2024</a>.
The approval of&nbsp;neffy&nbsp;1 mg&nbsp;is based on data from clinical trials, including pharmacokinetic (PK) and pharmacodynamic (PD) responses&nbsp;in pediatric and adult subjects&nbsp;consistent with those of epinephrine injection products.
Adverse events in pediatric trials were generally mild and transient.
The device has a shelf-life of 24 months at room temperature and tolerance to temperature exposures up to 122°F (50°C) based on testing for up to 3 months. If accidentally frozen, it can be thawed without impacting the product&#8217;s quality and reliability.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41876225/ars-pharmaceuticals-inks-licensing-pact-for-neffy-allergic-reaction-treatment-analyst-sees-further-stock-upside-despite-200-surge-in-2024" rel="noreferrer noopener">ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024</a>
Most commercially insured patients will pay no more than $25 for two single-use neffy devices through a co-pay savings program.
If the product isn&#8217;t covered by insurance, the&nbsp;cash price of $199 for two doses is available through BlinkRx and coupon can be downloaded from GoodRx for use at local retail pharmacies.
For certain uninsured or underinsured U.S. residents meeting eligibility criteria and exhausted all other options, the ARS Pharma Patient Assistance Program will provide&nbsp;neffy&nbsp;at no cost.
William Blair analyst Lachlan Hanbury-Brown writes, &#8220;While the approval was largely expected, we believe it nonetheless represents an important milestone for the company as it advances the launch of neffy 2 mg.&#8221;
The analyst noted that although Neffy 1 mg accounts for only about 15% of the epinephrine market by volume, the company&#8217;s research shows that needle phobia is most common in children.
Many caregivers are also hesitant to use needle-based autoinjectors on their children, which could drive higher adoption of neffy among pediatric patients.
In the U.S., nearly 40% of epinephrine prescriptions are for children. Since its September launch, about two-thirds of Neffy 2 mg prescriptions have been for children, indicating strong early adoption in this group.
Price Action: SPRY stock is down 1.29% at $10.73 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44149088/disney-cuts-200-jobs-across-abc-and-tv-networks-amid-restructuring" target="_blank" rel="noreferrer noopener">Disney Cuts 200 Jobs Across ABC News And Disney Entertainment Networks: Report</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

SPRY

FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray For Emergency Allergy Treatment

RBC Capital analyst Michael Carroll maintains Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) with a Outperform and lowers the price target from $81 to $74.

LINE

RBC Capital Maintains Outperform on Lineage, Lowers Price Target to $74

Loop Capital analyst Gary Mobley upgrades Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) from Hold to Buy and announces $110 price target.

Upgrades

MRVL

Loop Capital Upgrades Marvell Tech to Buy, Announces $110 Price Target

Insider Trades

AIM ImmunoTech Form 4 Filing Shows CEO Thomas K Equels Bought 50,000 Shares At An Average Price Of $0.13/Share

RBC Capital analyst Michael Carroll maintains EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>) with a Outperform and raises the price target from $50 to $58.

RBC Capital Maintains Outperform on EPR Props, Raises Price Target to $58

Macro Economic Events

Economics

Federal Reserve

Fed's Harker Says It Never Turns Out Well When Central Bank Independence Is Eroded; Worried That Decline In Inflation Pressure Is At Risk

RBC Capital analyst Nik Modi reiterates Brown-Forman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) with a Sector Perform and maintains $44 price target.

Reiteration

BF/B

RBC Capital Reiterates Sector Perform on Brown-Forman, Maintains $44 Price Target

Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC ("Nasdaq") Hearing Panel (the "Panel") and requested an extension of time to achieve compliance with Nasdaq Listing Rules 5450(a)(1), 5450(b)(2&amp;3)(C) and 5450(b)(2)(A), the Minimum Bid Price ("Bid Price"), Market Value of Publicly Held Shares ("MVPHS") and Market Value of Listed Securities ("MVLS") rules, respectively.
On March 5, 2025, the Company received a written notification (the "Notice") from the Panel confirming it has granted the Company such an extension for the Company to regain compliance with the MVPHS and MVLS rules, provided that the Company, (i) on or before March 12, 2025, files an application to transfer to the Nasdaq Capital Market, which it intends to do, and (ii) on or before March 31, 2025, demonstrates compliance with all Nasdaq listing rules, which it also intends to do, and believes it will satisfy.
Additionally, the Company was also notified in the Notice that as of February 26, 2025, it had regained compliance with Nasdaq Listing Rule 5450(a)(1), the Bid Price rule.
Following the transfer to the Nasdaq Capital Market, the Company's current MVPHS will be compliant with the MVPHS continued listing standard of greater than $1.0 million and the Company believes it will be able to demonstrate its compliance with the Equity Standard of Stockholder's Equity greater than $2.5 million prior to the March 31, 2025, deadline to the satisfaction of Nasdaq, although no such assurance can be given.

Conduit Pharmaceuticals Received Written Notification From The Panel Confirming It Has Granted The Co An Extension To Regain Compliance On Or Before March 12, 2025

Piper Sandler analyst Harsh Kumar maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Overweight and lowers the price target from $120 to $95.

Piper Sandler Maintains Overweight on Marvell Tech, Lowers Price Target to $95

Aclarion Announces Expansion Of Nociscan Access In New York And New Jersey With RadNet Affiliates To Meet Growing Demand

RBC Capital analyst Deane Dray maintains Eaton Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) with a Outperform and lowers the price target from $405 to $376.

RBC Capital Maintains Outperform on Eaton Corp, Lowers Price Target to $376

Barclays analyst Raimo Lenschow maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Overweight and lowers the price target from $330 to $280.

Barclays Maintains Overweight on MongoDB, Lowers Price Target to $280

Piper Sandler analyst Brent Bracelin maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Overweight and lowers the price target from $425 to $280.

Piper Sandler Maintains Overweight on MongoDB, Lowers Price Target to $280

In the current market session, AutoZone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) stock price is at $3544.81, after a 0.31% drop. However, over the past month, the company's stock spiked by 2.25%, and in the past year, by 15.11%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1741272347_0.png" alt="Past Year Chart" />

<h3>AutoZone P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
AutoZone has a lower P/E than the aggregate P/E of 25.24 of the Specialty Retail industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1741272347_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Comments

HOOKIPA Pharma

Noticias

Últimas noticias sobre HOOKIPA Pharma (NASDAQ:HOOK) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL